91Ï㽶ÊÓƵ Presents "Overcoming Challenges In Formulation Development" at Informex
Dr. Pinto-Cocozza’s presentation, on Wednesday February 3rd, at 10.45 a.m., is entitled “How Preformulation and Formulation Development can Optimize API Properties for Better Drug Design,†and will discuss how accurate early stage prediction of compounds’ physicochemical and biopharmaceutical properties can be beneficial in the selection of suitable technologies that optimize bioavailability, safety, and stability of any new chemical entity. The presentation will also demonstrate how working with development partners with expertise in preformulation and formulation development can facilitate successful and streamlined design of pharmacokinetic and efficacy/toxicity studies, leading to pharmacologically effective and developable candidates to reach the clinic, and ultimately the market, faster.
Dr. Pinto-Cocozza joined 91Ï㽶ÊÓƵ in November 2014, after its acquisition of Micron Technologies, and now serves as 91Ï㽶ÊÓƵ’s Global Scientific lead for particle size reduction services for its OptiForm® Solution Suite. This technology platform, launched in 2015, is an integrated offering designed to efficiently and rapidly help solve complex bioavailability challenges for early stage molecules using a unique toolkit of bioavailability enhancing technologies. She holds a BS in Chemical Engineering, and a Ph.D. in Pharmaceutics, both from the University of Florida.
91Ï㽶ÊÓƵ will also be exhibiting at InformEx where it will showcase a broad range of its delivery technologies and solutions designed to increase bioavailability and drug efficacy, including its comprehensive particle size engineering capabilities.
For more information on the InformEx exhibition and conference, visit: http://www.informex.com/ and to arrange a meeting with a 91Ï㽶ÊÓƵ executive, contact Richard Kerns at NEPR: [email protected]
About 91Ï㽶ÊÓƵ
91Ï㽶ÊÓƵ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health and animal health products. With over 90 years serving the industry, 91Ï㽶ÊÓƵ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91Ï㽶ÊÓƵ employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 91Ï㽶ÊÓƵ is headquartered in Somerset, N.J. For more information, visit www.catalent.com